Evidence map›Paper›PMID 27147570›Full record

ArticleOncotarget2016

Assessment of red blood cell distribution width as a prognostic marker in chronic lymphocytic leukemia.

Monika Podhorecka, Dorota Halicka, Agnieszka Szymczyk, Arkadiusz Macheta, Sylwia Chocholska, Marek Hus, Zbigniew Darzynkiewicz

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Clinicopathologic Characterization of Prostatic Cancer in Dogs.Animals : an open access journal from MDPI · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Monika PodhoreckaDepartment of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.
Dorota HalickaDepartment of Pathology, New York Medical College, Valhalla, New York, USA.
Agnieszka SzymczykDepartment of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.
Arkadiusz MachetaDepartment of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.
Sylwia ChocholskaDepartment of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.
Marek HusDepartment of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.
Zbigniew DarzynkiewiczDepartment of Pathology, New York Medical College, Valhalla, New York, USA.
Medical University of Lublin · PLNew York Medical College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Red blood cell distribution width (RDW) is a quantitative measure of the variability in size of circulating erythrocytes. It was recently reported that RDW is a prognostic factor for infection diseases, cardiovascular and pulmonary diseases, as well as some neoplasms. Moreover, RDW is remarkably strong predictor of longevity, including all causes of death, for adults aged 45 years and older. To explain this occurrence it was proposed that persistent IGFs/mTOR signaling is one of the factors that play a role in affecting the RDW and mortality.The above observations induced us to analyze the prognostic role of RDW in chronic lymphocytic leukemia (CLL) being the most frequent type of adult leukemia in Western countries. The obtained results have shown that RDW may be considered as a potential CLL prognostic marker. Elevated RDW level at the moment of diagnosis was associated with advanced disease and presence of other poor prognostic factors. It is also connected with overall survival indicating shorter time in patients with elevated RDW. It is possible that the presently observed correlation between mortality and RDW of the CLL patients is affected by their metabolic (IGF-1/mTOR driven)- rather than chronological- aging. The patients with high level of RDW are expected to have an increased persistent level of IGF-1/mTOR signaling. Within the framework of personalized therapy, these CLL patients therefore would be expected to be more sensitive to the treatment with mTOR inhibitors.

Indexed as

Erythrocyte IndicesErythrocytesAdultAgedAged, 80 and overAntineoplastic AgentsFemaleHumansInsulin-Like Growth Factor IKaplan-Meier EstimateLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedMolecular Targeted TherapyPredictive Value of TestsPrognosisAntineoplastic AgentsIGF1 protein, humanInsulin-Like Growth Factor IMTOR protein, humanProtein Kinase InhibitorsTOR Serine-Threonine KinasesCD38CLLmTORRDWZAP-70

Identifiers

PMID27147570
PMCPMC5078056
OpenAlexW2345141118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.